Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 137 | 1 | 117 | −19 |
| Shares | 64.0M | 254 | 57.4M | −6.62M (−10.3%) |
| Value | $401.4M | $1.59K | $550.5M | +$149.1M (+37.1%) |
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Catalio Capital Management, LP | 672,290 | $6.45M | 1.35% |
| Moore Capital Management, LP | 600,000 | $5.75M | 0.11% |
| Schonfeld Strategic Advisors LLC | 306,399 | $2.94M | 0.02% |
| Susquehanna Portfolio Strategies, LLC | 267,962 | $2.57M | 0.06% |
| Ameriprise Financial Inc | 180,851 | $1.73M | 0.00% |
| Diadema Partners LP | 40,294 | $386.4K | 0.24% |
| Brevan Howard Capital Management LP | 27,834 | $266.9K | 0.00% |
| Birchview Capital, LP | 25,000 | $239.8K | 0.24% |
| Private Advisor Group, LLC | 14,580 | $139.8K | 0.00% |
| Axq Capital, LP | 13,620 | $130.6K | 0.04% |
| Entropy Technologies, LP | 11,600 | $111.2K | 0.01% |
| Persistent Asset Partners Ltd | 9,421 | $90.3K | 0.08% |
| Raymond James Financial Inc | 3,174 | $30.4K | 0.00% |
| C M Bidwell & Associates Ltd | 1,122 | $10.8K | 0.01% |
| Quarry LP | 1,024 | $9.82K | 0.00% |
| Jones Financial Companies LLLP | 465 | $4.53K | 0.00% |
| Fortitude Family Office, LLC | 208 | $2.00K | 0.00% |
Sold out (36)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (1)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Lindbrook Capital, LLC | 254 | $1.59K |